A human T-lymphotropic virus type I (HTLV-I) strain was isolated in a CD4+ T- of HTLV-IMSHR-l is also divergent. The potential for antigenic divergence between the prototype HTLV-I isolates and the Austro-Melanesian variants requires further investigation, because it would have implications for serodiagnosis and vaccine development.
Human T-lymphotropic virus type I (HTLV-I) is a retrovirus associated with the lymphoid malignancy adult T-cell leukemia-lymphoma and the neurological disease tropical spastic paraparesis (13, 18) . The virus is endemic in Japan, Africa, and the Caribbean (6, 33) . Recent studies have found a high prevalence of HTLV-I antibodies in Melanesia and among Australian Aboriginals (2, 21, 27) . These findings have been controversial because of equivocal serological results and limited evidence of the associated diseases (1, 22, 50) . Recent isolation and sequencing of HTLV-I variants from Papua New Guinea and the Solomon Islands has confirmed the existence of the virus in Melanesia (14, 51, 52) . This report verifies the presence of a similar HTLV-I strain among Australian Aboriginals.
MATERIALS AND METHODS
Samples. Protocols for this project were approved by the Institutional Ethics Committee of the Royal Darwin Hospital, which adhered to the guidelines of the National Health and Medical Research Council of Australia (30) ; the committee has Aboriginal representation.
A pilot survey had found serological evidence of HTLV-I among the Aboriginal population of the Northern Territory by using the Serodia ATLA particle agglutination assay (Fujirebio Inc., Tokyo, Japan), and the evidence was confirmed by stringent Western blot (immunoblot) criteria (5, 31) . In August 1988, a blood sample was collected from an HTLV-I-seropositive Aboriginal living in an isolated community. The specimen was placed in a heparinized tube and maintained at ambient temperature until delivery to the laboratory 20 h later. After Ficoll (Pharmacia LKB Biotechnology Inc., Piscataway, N.J.) separation, the peripheral blood mononuclear cells (PBMCs) were stored in liquid nitrogen.
For the coculture experiment, fresh PBMCs were obtained by Ficoll separation of heparinized blood from an anonymous blood donor who was seronegative by the Serodia HTLV particle agglutination assay (Fujirebio Inc.).
Cell culture. In April 1990, PBMCs from the HTLV-Iseropositive Aboriginal were removed from cryopreservation. Five million cells were placed in a 50-ml culture flask (A-S Nunc, Roskilde, Denmark) containing 5 ml of RPMI 1640 (GIBCO BRL Inc., Gaithersburg, Md.) plus 20% heatinactivated fetal calf serum (FCS) (GIBCO LT Ltd., Auckland, New Zealand) for 1 day, before stimulation with phytohemagglutinin (Sigma Chemical Co., St. Louis, Mo.) at 13 p,g/ml for 3 days. The cells were then cultivated in RPMI 1640 containing 20% FCS, 2% interleukin 2 (Pharmacia Diagnostics Inc., Silver Spring, Md.), 100 ,g of streptomycin (CSL, Parkville, Victoria, Australia) per ml, and 100 ,ug of vancomycin (DBL, Mulgrave, Victoria, Australia) per ml. The medium was changed each third or fourth day, and the cell density was maintained below 106/ml.
Immunofluorescence. Indirect immunofluorescence was used to detect viral antigens in cell culture. A 10-,ul volume of a cell suspension (106 cells per ml) was dried at room temperature on each well of eight-well frosted slides (Flow Laboratories, North Ryde, New South Wales, Australia). Slides were placed in acetone for 15 min and washed in phosphate-buffered saline (PBS). Fixed cells were incubated at 37°C for 1 h with murine monoclonal antibody to HTLV p19 or p24 (MAS197, MAS198, or MAS199; Sera-Lab Ltd., Crawley Down, Sussex, England) or to HTLV-I gp46 (1C11; Olympus Corp., Lake Success, N.Y.) (35) (36) (37) . After the cells were washed in PBS, bound antibody was detected by incubation at 37°C for 1 h with sheep antimouse immunoglobulin G conjugated to fluorescein isothiocyanate (Silenus Laboratories Pty. Ltd., Hawthorn, Victoria, Australia). Slides were examined by using a Leitz Dialux 22 fluorescence microscope. Controls included an HTLV-I-positive cell line (MT-2) (28) , an uninfected T-cell culture (HUT-78), human B cells transformed by Epstein-Barr virus, and an anti-B-cell mouse monoclonal antibody; a PBS-1% bovine sulfate (SDS), 0.5% BLOTTO (10% nonfat milk powder plus 0.2% sodium azide), 5% dextran sulfate, and 500 ,g of heat-denatured herring sperm DNA per ml. The membrane was washed at ambient temperature in 6x SSC-0.1% SDS and then at 50 to 600C in 2x SSC-0.1% SDS before being exposed to X-ray film (lx SSC is 0.15 M NaCl plus 0.015 M sodium citrate).
Amplified products of the expected sizes ( Table 1 ) that hybridized with internal oligonucleotide probes were separated from the remaining reaction mixture by electrophoresis in a 2% low-melting-point agarose gel (Bio-Rad Laboratories, Richmond, Calif.). The band of interest was cut from the gel and DNA precipitated in ethanol after two phenol extractions. The PCR product was ligated into the pUC18 vector by using T4 DNA ligase (Promega, Rozelle, New South Wales, Australia) and then transformed into Escherichia coli JM109. Inclusion of restriction sites in the 5' ends of the env primers facilitated the ligation step. The insert was sequenced by the dideoxynucleotide chain termination method with Sequenase Version 2.0 (U.S. Biochemical, Cleveland, Ohio). Sequences from the env and pX regions were verified by sequencing at least two products amplified in different PCRs.
Syncytium inhibition assay. The method of Nagy et al. (29) HTLV-I-infected lymphocytes were incubated with human serum (10% final concentration) for 18 h in RPMI 1640 containing 20% FCS. Cultures were fixed in methanol, stained with Giemsa, and examined for syncytium formation.
Other procedures. To demonstrate the presence of infective virus particles, putatively infected cells were cocultivated with PBMCs from an HTLV-I-seronegative, non-Aboriginal blood donor (40) . Positive cells were preincubated with 100 p,g of mitomycin per ml (Sigma Chemical Co., St. Louis, Mo.) for 20 min at 37°C and washed. Negative cells were incubated for 3 parisons were performed by using the Clustal V software package (17) .
Nucleotide sequence accession numbers. The GenBank accession numbers for the env, pX, and two pol nucleotide sequences of HTLV-IMSHR-l are M92818, M92819, M92820, and M92821, respectively.
RESULTS
Detection of HTLV-I in lymphocyte cultures. After 7 weeks of culture, PBMCs from the HTLV-I-seropositive Aboriginal subject developed the features of an HTLV-I-infected cell line (40) . Cells proliferated rapidly with a doubling time of less than 24 h and were passaged each third or fourth day. The cells were CD3+ CD4+ CD8-CD25+ mature T lymphocytes that expressed high levels of HLA-DR antigens. This T-cell culture was named MSHR-1.
HTLV antigens were detected in MSHR-1 by indirect immunofluorescence (Fig. 1) The coculture experiment confirmed that MSHR-1 was producing infective virus particles. After 2 months, viral antigens were detected in the coculture by indirect immunofluorescence with anti-p19 monoclonal antibody MAS198. The cocultured cells were CD3+ CD4+ CD8-mature T lymphocytes, of which over 90% expressed the interleukin 2 receptor and HLA-DR antigens. They had the following HLA phenotype: A2, A30; B18,-. In contrast, MSHR-1 was A34,-; B13, B61. PBMCs (5 x 106) from the seronegative blood donor were cultured as described in Materials and Methods but without addition of mitomycin-treated MSHR-1 cells. This culture could be maintained for only 3 months, viral antigens were not detected in the culture by indirect immunofluorescence, and PCR failed to amplify proviral sequences in DNA extracted from these cells (Fig. 2) .
DNA amplification and sequencing. With the pol, env, and pX primers, PCR products of the expected sizes (Table 1) were amplified from DNA extracted from MSHR-1. These products hybridized with internal probes under stringent conditions (Fig. 2) .
Sequencing of the env gene of HTLV-IMSHR1 showed a divergence at the nucleotide level of 6.5 to 7% (i.e., 95 to 102 substitutions in 1,451 bases) from the Caribbean, African, and Japanese strains (15, 25, 33) , which are over 98% homologous (Table 2) . Nucleotide changes were more often conservative, with only 3.1 to 4.3% divergence in the predicted amino acid sequence ( Table 2 ). The signal peptide was the most variable region, with four changes in 20 amino acids (Fig. 3) . Other amino acid changes clustered within the N-terminal portion of the transmembrane protein. The potential glycosylation sites, the cysteine residues, and the putative immunosuppressive peptide (8) were all conserved. The 139 bases lying between the primers in thepX product were sequenced. This segment is part of the region where the tax and rex genes overlap. Although three other HTLV-I isolates (25, 33, 44) are identical within this segment, HTLV-IMSHR-1 contained four nucleotide changes (i.e., 2.9% divergence). None of the substitutions caused an amino acid coding change in the tax reading frame, but all four caused a change in the rex reading frame.
Sequencing of multiple clones containing env and pX products from repeated PCRs revealed only one discrepant nucleotide in over 5,700 bases. A conservative change (C--T) was noted at the first base in the triplet that codes for leucine at residue 320 of the envelope precursor (Fig. 3 ) when we sequenced a product amplified from DNA extracted from MSHR-1 within 6 weeks of commencement of the culture. This substitution was not found in the amplified products of later DNA extracts from MSHR-1.
Two portions of the pol gene were amplified and sequenced: 352 bases from the central portion and 317 bases at the 3' end of the gene. The divergence of HTLV-IMSHR-l from HS35 and ATK-1 (25, 44) was comparable in these two segments. While the Japanese and Caribbean isolates varied by 1.9% at the nucleotide level, HTLV-IMSHRl1 diverged by more than 6% from the other two strains. The splice acceptor and donor sites were conserved.
Syncytium inhibition assay. Syncytia formed when MSHR-1 lymphocytes were cultured with HeLa cells, rat XC cells, and HL cells but not when they were cultured with baby hamster kidney (BHK) cells. HeLa cells were judged to be better as indicator cells for syncytium inhibition assays with MSHR-1. Sera from 10 Aboriginal HTLV-I carriers, whose seropositivity had been confirmed by stringent Western blot criteria (31), repeatedly inhibited syncytium formation (Fig. 4) . Sera from eight seronegative Aboriginals had no inhibitory effect. MT-2
* *** * *** * ** ******* *** * ***** ********* * * ** *** **** * ** ******* **** imnunosuppressive peptide memb. span. ************************ ********* * *** ******** ** *************Sr********** memb. span. viral enzymes, including reverse transcriptase. The env gene produces a precursor protein that comprises a signal peptide, an envelope glycoprotein (gp46), and a transmembrane protein (gp2l). ThepX region contains four open reading frames and is transcribed in a multiply spliced mRNA. Translation of different reading frames in this mRNA produces regulatory proteins tax and rex (11) . The nucleotide and predicted amino acid sequences of the Japanese, Caribbean, and African isolates are over 98% homologous within the segments of the pol, env, and pX genes studied. The greater divergence of MSHR-1 (Tables 2 and 3) the Solomon Islands (14) . Within a 522-bp segment of the env gene, those strains were approximately 8% divergent from the prototype Japanese sequence (44) . As with the Melanesian isolates, the divergence of HTLV-IMSHR-l suggests that it was not introduced recently to the Aboriginal population but represents the persistence of an ancient virus that was present among the early inhabitants of Sahul Land (14) . A phylogenetic tree (Fig. 5) . constructed after aligning the Papua New Guinean nucleotide sequence with the comparable regions of HTLV-IMsHRl and other HTLV-I isolates (14, 25, 33) supports the hypothesis that the Melanesian and Australian strains have a common ancestry. Antigenic divergence. There is evidence of antigenic divergence in the p19 core protein, in that MSHR-1 reacted with one anti-p19 monoclonal antibody (MAS198) but was negative with another (MAS197). Similarly, a p19 antigen capture assay (38) employing a murine monoclonal antibody (clone 6.11) failed to detect the p19 antigen in the supernatant of MSHR-1. Thus, two monoclonal antibodies (MAS197 and 6.11) seem to recognize epitopes in the p19 core protein of prototype HTLV-I isolates which are strain specific and absent from the Australian HTLV-I variant. The gag gene of HTLV-IMSHR-1, which encodes the p19 protein, must be sequenced to identify the molecular basis for this antigenic diversity.
The syncytium inhibition assays demonstrate that sera from Aboriginal HTLV-I carriers can (45) . The segment spans bases 6068 to 6589 as numbered for the prototype sequence (44) in the EMBL data base. The analysis was performed by using the Clustal V multiple sequence alignment package (17) . Branch lengths are in parentheses. Antigenic divergence between prototype and AustroMelanesian strains could also affect serodiagnosis. Reactivity with the products of two genes (e.g., gag and env) is required to confirm HTLV-I seropositivity by Western blot (31, 41) . The C-terminal end of gp46 contains immunoreactive epitopes (7, 19) . HTLV-IMSHR1 has only four changes (three of which are conservative) in 138 amino acids compared with the overseas isolates. However, single amino acid changes in the envelope glycoproteins of human immunodeficiency virus, HTLV-I, and bovine leukemia virus led to altered antigenicity (26, 42, 43 (20) .
Sequences from repeated PCRs demonstrated the fidelity of the Taq enzyme, with only one possible misincorporation in over 5,500 bases. Another possibility is that this discrepant nucleotide is a conservative substitution in a variant clone which was overgrown while cultivating MSHR-1.
Summary. An HTLV-I strain was isolated from an Australian Aboriginal. The proviral genome differs from the prototype sequences and is related to the Melanesian isolates. The effect of this divergence on serodiagnosis and virus neutralization requires further investigation. Although adult T-cell leukemia-lymphoma has been reported in an Aboriginal HTLV-I carrier (22) , the infrequent occurrence of adult T-cell leukemia-lymphoma or tropical spastic paraparesis may be of limited importance to the public health of Melanesians and Aborigines. With the continuing load of infectious diseases and the impending threat of the human immunodeficiency virus epidemic, the putative immunosuppressive action of HTLV-I and the accelerated progression to AIDS of patients coinfected with HTLV-I and human immunodeficiency virus could be of greater relevance to the health of these indigenous communities (4, 16, 32, 46) .
